- Home
- CSTL vs GOOD Comparison
CSTL vs GOOD Comparison
Compare CSTL & GOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GOOD
- Stock Information
- Founded
- CSTL 2007
- GOOD 2003
- Country
- CSTL United States
- GOOD United States
- Employees
- CSTL N/A
- GOOD N/A
- Industry
- CSTL Medical Specialities
- GOOD Real Estate Investment Trusts
- Sector
- CSTL Health Care
- GOOD Real Estate
- Exchange
- CSTL Nasdaq
- GOOD Nasdaq
- Market Cap
- CSTL 661.7M
- GOOD 578.7M
- IPO Year
- CSTL 2019
- GOOD N/A
- Fundamental
- Price
- CSTL $22.14
- GOOD $11.50
- Analyst Decision
- CSTL Strong Buy
- GOOD
- Analyst Count
- CSTL 6
- GOOD 0
- Target Price
- CSTL $37.67
- GOOD N/A
- AVG Volume (30 Days)
- CSTL 296.4K
- GOOD 513.5K
- Earning Date
- CSTL 11-03-2025
- GOOD 11-03-2025
- Dividend Yield
- CSTL N/A
- GOOD 10.44%
- EPS Growth
- CSTL N/A
- GOOD N/A
- EPS
- CSTL N/A
- GOOD 0.36
- Revenue
- CSTL $346,269,000.00
- GOOD $153,643,000.00
- Revenue This Year
- CSTL N/A
- GOOD $7.51
- Revenue Next Year
- CSTL N/A
- GOOD $4.39
- P/E Ratio
- CSTL N/A
- GOOD $32.29
- Revenue Growth
- CSTL 20.40
- GOOD 5.85
- 52 Week Low
- CSTL $14.59
- GOOD $11.26
- 52 Week High
- CSTL $35.84
- GOOD $17.88
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- GOOD 30.27
- Support Level
- CSTL $22.16
- GOOD $11.26
- Resistance Level
- CSTL $23.19
- GOOD $11.81
- Average True Range (ATR)
- CSTL 0.89
- GOOD 0.24
- MACD
- CSTL -0.16
- GOOD -0.00
- Stochastic Oscillator
- CSTL 10.05
- GOOD 23.18
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.